ANAB

AnaptysBio, Inc.

ANAB | $18.93 -1.3% 32K

(0.0% 1d) (-9.1% 1m) (-10.8% 1y) (0.0% 2d) (-2.4% 3d) (-3.5% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 506,625,123
http://www.anaptysbio.com
Sec Filling | Patents | 89 employees

(US) AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

antibody

add to watch list Paper trade email alert is off

Press-releases

Actym Therapeutics Appoints Thomas Smart as CEO
Published: 2024-04-24 (Crawled : 13:00) - prnewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| 0.0% | O: -1.72% H: 0.0% C: 0.0%
ceo smart therapeutics

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| -17.86% | O: 15.2% H: 0.37% C: -3.12%
business year update financial results

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Published: 2024-02-29 (Crawled : 14:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| -25.69% | O: 1.63% H: 0.84% C: -2.67%
conference health care meeting

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 14:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| -19.85% | O: -0.63% H: 3.49% C: -0.76%
conference

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
Published: 2023-11-27 (Crawled : 21:00) - globenewswire.com
CNTA | News | $8.94 -4.89% 840K

Manufacturing

| 52.0% | O: -1.69% H: 1.78% C: -6.1%
ANAB | $18.93 -1.3% 32K

Health Technology

| 37.99% | O: 0.0% H: 2.45% C: -0.36%
antibody license pipeline cell pharmaceuticals

Anaptys Named a BioSpace 2024 Best Places to Work Winner
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| 16.1% | O: 1.33% H: 0.0% C: -7.41%
work

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| 18.4% | O: 8.89% H: 5.27% C: -0.62%
update financial results

Anaptys Announces Participation in November Investor Conferences
Published: 2023-11-01 (Crawled : 13:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| 17.6% | O: -1.04% H: 3.84% C: 2.48%

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study
Published: 2023-10-13 (Crawled : 07:00) - anaptysbio.com
ANAB | $18.93 -1.3% 32K

Health Technology

| 3.28% | O: -0.32% H: 2.22% C: 1.78%
anb032 agonist cell results study

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
Published: 2023-10-11 (Crawled : 13:00) - globenewswire.com
ANAB | $18.93 -1.3% 32K

Health Technology

| -2.09% | O: -0.15% H: 0.26% C: -0.56%
anb032 agonist congress

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-009164	4	2024-03-27	2024-03-26	Sell	F	347441	401646
0001415889-24-009164	4	2024-03-27	2024-03-25	Sell	S	3000	749087
0001415889-24-009164	4	2024-03-27	2024-03-22	Sell	S	145940	752087
0001415889-24-002204	4	2024-02-01	2024-01-30	Sell	S	3065	964
0001209191-24-001280	4	2024-01-10	2024-01-06	Sell	M	6145	18435
0001209191-24-001280	4	2024-01-10	2024-01-08	Sell	S	2554	10118
0001209191-24-001280	4	2024-01-10	2024-01-06	Buy	M	6145	12672
0001209191-24-001279	4	2024-01-10	2024-01-06	Sell	M	5545	16635
0001209191-24-001279	4	2024-01-10	2024-01-08	Sell	S	2305	3240
0001209191-24-001279	4	2024-01-10	2024-01-06	Buy	M	5545	5545